Asset Details
Do you wish to reserve the book?
Plasma levels of fibrinolytic and coagulation biomarkers in HIV‐infected individuals on highly active antiretroviral therapy: A case‐control study in a Northern Ghanaian population
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plasma levels of fibrinolytic and coagulation biomarkers in HIV‐infected individuals on highly active antiretroviral therapy: A case‐control study in a Northern Ghanaian population
Do you wish to request the book?
Plasma levels of fibrinolytic and coagulation biomarkers in HIV‐infected individuals on highly active antiretroviral therapy: A case‐control study in a Northern Ghanaian population
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plasma levels of fibrinolytic and coagulation biomarkers in HIV‐infected individuals on highly active antiretroviral therapy: A case‐control study in a Northern Ghanaian population
2023
Overview
Background and Aim Impaired coagulation and fibrinolysis have been implicated in thromboembolism in human immunodeficiency virus (HIV)‐infected individuals. This study evaluated the plasma levels of plasminogen activator inhibitor‐1 (PAI‐1) and coagulation biomarkers in HIV‐infected individuals on highly active antiretroviral therapy (HAART). Methods This matched case‐control study from March to December, 2020 comprised 76 participants: 38 HIV‐positive individuals on HAART and 38 apparently healthy HIV‐negative individuals as controls. Blood samples were collected for prothrombin time (PT), activated partial thromboplastin time (aPTT), D‐dimers, PAI‐1, and soluble fibrin monomer complex (SFMC) estimations. The data were analysed using SPSS version 22.0 and statistical significance was set at p < 0.05. Results Activated partial thromboplastin time was significantly lower in HIV seropositive individuals on HAART compared with HIV seronegative controls (25.90 s vs. 29.0 s, p = 0.030); however, PT, SFMC, D‐dimers, and PAI‐1 were significantly higher among the HIV‐seropositive individuals compared with the controls: PT: (16.29 s ± 2.16 vs. 15.15 s ± 2.60, p = 0.010), SFMC: [8.53 ng/mL (8.03–9.12) vs. 7.84 ng/mL (7.32–8.58), p = 0.005]), D‐Dimer: [463.37 ng/mL (402.70–526.33) vs. 421.11 ng/mL (341.11–462.52), p = 0.015], and PAI‐1: [12.77 ng/mL (10.63–14.65) vs. 11.27 ng/mL (10.08–12.95), p = 0.039]. PAI‐1 showed a moderate positive correlation with D‐Dimer (r = 0.659, p < 0.001) and SFMC (r = 0.463, p = 0.003) among HIV‐positive individuals on HAART. There was a strong positive correlation between the plasma PAI‐1 concentration and the HIV viral load (r = 0.955, p < 0.001). Conclusion HIV‐seropositive individuals on HAART have deranged coagulation and fibrinolytic markers. Higher HIV viral load correlates strongly with elevated plasma levels of PAI‐1 antigens. Periodic assessment of markers of coagulation and fibrinolysis be included in the management of HIV/AIDS in Ghana.
